Global Neuroprotective Drugs Market Intelligence Report for Comprehensive Information 2018-2025

Request for a SAMPLE REPORT

Fill up your details below and get the sample report for FREE

 Published Date : Oct-2018   |    Format :PDF   |    Number of Pages : 110
This report studies the global market size of Neuroprotective Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroprotective Drugs in these regions.
This research report categorizes the global Neuroprotective Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
In 2017, the global Neuroprotective Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Neuroprotective Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Neuroprotective Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Neuroprotective Drugs include
    Genervon Biopharmaceuticals (Canada)
    NeuroVive Pharmaceutical (Sweden)
    Ceregene (USA)
    BHRPharma (Thailand)
    Neuren Pharmaceuticals (Australia)
    Allon therapeutics (Canada)
    Bionure Inc. (USA)

Market Size Split by Type
    Cholinesterase inhibitors
    Anti-inflammatory
    Others
Market Size Split by Application
    Alzheimer's disease
    Parkinson's disease
    Others

Market size split by Region
    North America
        United States
        Canada
        Mexico
    Asia-Pacific
        China
        India
        Japan
        South Korea
        Australia
        Indonesia
        Singapore
        Malaysia
        Philippines
        Thailand
        Vietnam
    Europe
        Germany
        France
        UK
        Italy
        Spain
        Russia
    Central & South America
        Brazil
        Rest of Central & South America
    Middle East & Africa
        GCC Countries
        Turkey
        Egypt
        South Africa

The study objectives of this report are:
    To study and analyze the global Neuroprotective Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
    To understand the structure of Neuroprotective Drugs market by identifying its various subsegments.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    Focuses on the key global Neuroprotective Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
    To analyze the Neuroprotective Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
    To project the value and volume of Neuroprotective Drugs submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Neuroprotective Drugs are as follows:
    History Year: 2013-2017
    Base Year: 2017
    Estimated Year: 2018
    Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroprotective Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

1 Study Coverage
    1.1  Neuroprotective Drugs Product
    1.2 Key Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Neuroprotective Drugs Market Size Growth Rate by Type
        1.4.2 Cholinesterase inhibitors
        1.4.3 Anti-inflammatory
        1.4.4 Others
    1.5 Market by Application
        1.5.1 Global Neuroprotective Drugs Market Size Growth Rate by Application
        1.5.2 Alzheimer's disease
        1.5.3 Parkinson's disease
        1.5.4 Others
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Neuroprotective Drugs Market Size
        2.1.1 Global Neuroprotective Drugs Revenue 2016-2025
        2.1.2 Global Neuroprotective Drugs Sales 2016-2025
    2.2 Neuroprotective Drugs Growth Rate by Regions
        2.2.1 Global Neuroprotective Drugs Sales by Regions
        2.2.2 Global Neuroprotective Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Neuroprotective Drugs Sales by Manufacturers
        3.1.1 Neuroprotective Drugs Sales by Manufacturers
        3.1.2 Neuroprotective Drugs Sales Market Share by Manufacturers
        3.1.3 Global Neuroprotective Drugs Market Concentration Ratio (CR5 and HHI)
    3.2 Neuroprotective Drugs Revenue by Manufacturers
        3.2.1 Neuroprotective Drugs Revenue by Manufacturers (2016-2018)
        3.2.2 Neuroprotective Drugs Revenue Share by Manufacturers (2016-2018)
    3.3 Neuroprotective Drugs Price by Manufacturers
    3.4 Neuroprotective Drugs Manufacturing Base Distribution, Product Types
        3.4.1 Neuroprotective Drugs Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Neuroprotective Drugs Product Category
        3.4.3 Date of International Manufacturers Enter into Neuroprotective Drugs  Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
    4.1 Global Neuroprotective Drugs Sales by Type
    4.2 Global Neuroprotective Drugs Revenue by Type
    4.3 Neuroprotective Drugs Price by Type

5 Breakdown Data by Application
    5.1 Overview
    5.2 Global Neuroprotective Drugs Breakdown Data by Application

6 North America
    6.1 North America Neuroprotective Drugs by Countries
        6.1.1 North America Neuroprotective Drugs Sales by Countries
        6.1.2 North America Neuroprotective Drugs Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Neuroprotective Drugs by Type
    6.3 North America Neuroprotective Drugs by Application
    6.4 North America Neuroprotective Drugs by Company

7 Europe
    7.1 Europe Neuroprotective Drugs by Countries
        7.1.1 Europe Neuroprotective Drugs Sales by Countries
        7.1.2 Europe Neuroprotective Drugs Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Neuroprotective Drugs by Type
    7.3 Europe Neuroprotective Drugs by Application
    7.4 Europe Neuroprotective Drugs by Company

8 Asia Pacific
    8.1 Asia Pacific Neuroprotective Drugs by Countries
        8.1.1 Asia Pacific Neuroprotective Drugs Sales by Countries
        8.1.2 Asia Pacific Neuroprotective Drugs Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Neuroprotective Drugs by Type
    8.3 Asia Pacific Neuroprotective Drugs by Application
    8.4 Asia Pacific Neuroprotective Drugs by Company

9 Central & South America
    9.1 Central & South America Neuroprotective Drugs by Countries
        9.1.1 Central & South America Neuroprotective Drugs Sales by Countries
        9.1.2 Central & South America Neuroprotective Drugs Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Neuroprotective Drugs by Type
    9.3 Central & South America Neuroprotective Drugs by Application
    9.4 Central & South America Neuroprotective Drugs by Company

10 Middle East and Africa
    10.1 Middle East and Africa Neuroprotective Drugs by Countries
        10.1.1 Middle East and Africa Neuroprotective Drugs Sales by Countries
        10.1.2 Middle East and Africa Neuroprotective Drugs Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Neuroprotective Drugs by Type
    10.3 Middle East and Africa Neuroprotective Drugs by Application
    10.4 Middle East and Africa Neuroprotective Drugs by Company

11 Company Profiles
    11.1 Genervon Biopharmaceuticals (Canada)
        11.1.1 Genervon Biopharmaceuticals (Canada) Company Details
        11.1.2 Company Description
        11.1.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.1.4 Neuroprotective Drugs Product Description
        11.1.5 Recent Development
    11.2 NeuroVive Pharmaceutical (Sweden)
        11.2.1 NeuroVive Pharmaceutical (Sweden) Company Details
        11.2.2 Company Description
        11.2.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.2.4 Neuroprotective Drugs Product Description
        11.2.5 Recent Development
    11.3 Ceregene (USA)
        11.3.1 Ceregene (USA) Company Details
        11.3.2 Company Description
        11.3.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.3.4 Neuroprotective Drugs Product Description
        11.3.5 Recent Development
    11.4 BHRPharma (Thailand)
        11.4.1 BHRPharma (Thailand) Company Details
        11.4.2 Company Description
        11.4.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.4.4 Neuroprotective Drugs Product Description
        11.4.5 Recent Development
    11.5 Neuren Pharmaceuticals (Australia)
        11.5.1 Neuren Pharmaceuticals (Australia) Company Details
        11.5.2 Company Description
        11.5.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.5.4 Neuroprotective Drugs Product Description
        11.5.5 Recent Development
    11.6 Allon therapeutics (Canada)
        11.6.1 Allon therapeutics (Canada) Company Details
        11.6.2 Company Description
        11.6.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.6.4 Neuroprotective Drugs Product Description
        11.6.5 Recent Development
    11.7 Bionure Inc. (USA)
        11.7.1 Bionure Inc. (USA) Company Details
        11.7.2 Company Description
        11.7.3 Sales, Revenue and Gross Margin of Neuroprotective Drugs
        11.7.4 Neuroprotective Drugs Product Description
        11.7.5 Recent Development

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    12.1 Market Opportunities and Drivers
    12.2 Market Challenges
    12.3 Market Risks/Restraints
    12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
    13.1 Value Chain Analysis
        13.1.1 Typical Suppliers of Key Neuroprotective Drugs Raw Material
        13.1.2 Neuroprotective Drugs Customers
    13.2 Sales Channels Analysis
        13.2.1 Sales Channels Analysis
        13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
            15.1.1.1 Research Programs/Design
            15.1.1.2 Market Size Estimation
            15.1.1.3 Market Breakdown and Data Triangulation
        15.1.2 Data Source
            15.1.2.1 Secondary Sources
            15.1.2.2 Primary Sources
    15.2 Author Details
    15.3 Disclaimer



List of Tables and Figures

    Figure Picture of Neuroprotective Drugs
    Figure Global Neuroprotective Drugs Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
    Figure Global Neuroprotective Drugs Production Market Share by Types (Product Category) in 2017
    Figure Cholinesterase inhibitors Product Picture
    Table Major Manufacturers of Cholinesterase inhibitors
    Figure Anti-inflammatory Product Picture
    Table Major Manufacturers of Anti-inflammatory
    Figure Others Product Picture
    Table Major Manufacturers of Others
    Table Global Neuroprotective Drugs Market Size Growth Rate by Application 2018-2025 (K Units)
    Figure Alzheimer's disease
    Figure Parkinson's disease
    Figure Others
    Figure Neuroprotective Drugs Report Years Considered
    Figure Global Neuroprotective Drugs Market Size 2016-2025 (Million US$)
    Figure Global Neuroprotective Drugs Sales 2016-2025 (K Units)
    Table Global Neuroprotective Drugs Market Size by Regions 2016-2025 (K Units) & (Million US$)
    Table Global Neuroprotective Drugs Sales by Regions 2016-2025 (K Units)
    Table Global Neuroprotective Drugs Sales Market Share by Regions 2016-2025
    Figure Global Neuroprotective Drugs Sales Market Share by Regions 2016-2025
    Figure 2017 Global Neuroprotective Drugs Sales Market Share by Regions
    Table Global Neuroprotective Drugs Revenue by Regions 2016-2025 (Million US$)
    Table Global Neuroprotective Drugs Revenue Market Share by Regions 2016-2025
    Figure Global Neuroprotective Drugs Revenue Market Share by Regions 2016-2025
    Figure 2017 Global Neuroprotective Drugs Revenue Market Share by Regions
    Table Global Neuroprotective Drugs Sales by Manufacturers (2016-2018) (K Units)
    Table Global Neuroprotective Drugs Sales Share by Manufacturers (2016-2018)
    Figure Global Neuroprotective Drugs Sales Share by Manufacturers in 2017
    Table Neuroprotective Drugs Revenue by Manufacturers (2016-2018) (Million US$)
    Table Neuroprotective Drugs Revenue Share by Manufacturers (2016-2018)
    Figure Neuroprotective Drugs Value Share by Manufacturers in 2017
    Table Global Neuroprotective Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table Key Manufacturers Neuroprotective Drugs Price (2016-2018) (USD/Unit)
    Table Neuroprotective Drugs Manufacturers Manufacturing Base Distribution and Headquarters
    Table Manufacturers Neuroprotective Drugs Product Category
    Table Date of International Manufacturers Enter into Neuroprotective Drugs Market
    Table Manufacturers Mergers & Acquisitions, Expansion Plans
    Table Global Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table Global Neuroprotective Drugs Sales Share by Type (2016-2025)
    Figure Global Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure Global Neuroprotective Drugs Sales Market Share by Type in 2017
    Table Global Neuroprotective Drugs Revenue by Type (2016-2025) (Million US$)
    Table Global Neuroprotective Drugs Revenue Share by Type (2016-2025)
    Figure Global Neuroprotective Drugs Revenue Market Share by Type (2016-2025)
    Figure Global Neuroprotective Drugs Revenue Market Share by Type in 2017
    Table Neuroprotective Drugs Price by Type 2013-2018 (USD/Unit)
    Table Global Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table Global Neuroprotective Drugs Sales Share by Application (2016-2025)
    Figure Global Sales Neuroprotective Drugs Market Share by Application (2016-2025)
    Figure Global Sales Neuroprotective Drugs Market Share by Application (2016-2025)
    Figure North America Neuroprotective Drugs Sales Growth Rate 2016-2025 (K Units)
    Figure North America Neuroprotective Drugs Revenue Growth Rate 2016-2025 (Million US$)
    Table North America Neuroprotective Drugs Sales by Countries (2016-2025) (K Units)
    Table North America Neuroprotective Drugs Sales Market Share by Countries (2016-2025)
    Figure 2017 North America Neuroprotective Drugs Sales Market Share by Countries
    Table North America Neuroprotective Drugs Revenue by Countries (2016-2025) (Million US$)
    Table North America Neuroprotective Drugs Revenue Market Share by Countries (2016-2025)
    Figure 2017 North America Neuroprotective Drugs Revenue Market Share by Countries
    Figure United States Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure United States Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Canada Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Canada Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Mexico Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Mexico Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Table North America Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table North America Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure 2017 North America Neuroprotective Drugs Market Share by Type
    Table North America Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table North America Neuroprotective Drugs Sales Market Share by Application (2016-2025)
    Figure 2017 North America Neuroprotective Drugs Market Share by Application
    Table North America Neuroprotective Drugs Sales by Company (2016-2018) (K Units)
    Table North America Neuroprotective Drugs Sales Market Share by Company (2016-2018)
    Figure North America Neuroprotective Drugs Sales Market Share by Company in 2017
    Figure Europe Neuroprotective Drugs Sales Growth Rate 2016-2025 (K Units)
    Figure Europe Neuroprotective Drugs Revenue Growth Rate 2016-2025 (Million US$)
    Table Europe Neuroprotective Drugs Sales by Countries (2016-2025) (K Units)
    Table Europe Neuroprotective Drugs Sales Market Share by Countries (2016-2025)
    Figure 2017 Europe Neuroprotective Drugs Sales Market Share by Countries
    Table Europe Neuroprotective Drugs Revenue by Countries (2016-2025) (Million US$)
    Table Europe Neuroprotective Drugs Revenue Market Share by Countries (2016-2025)
    Figure 2017 Europe Neuroprotective Drugs Revenue Market Share by Countries
    Figure Germany Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Germany Neuroprotective Drugs Revenue Growth Rate (2016-2025) (K Units)
    Figure France Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure France Neuroprotective Drugs Revenue Growth Rate (2016-2025) (K Units)
    Figure UK Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure UK Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Italy Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Italy Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Russia Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Russia Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Table Europe Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table Europe Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure 2017 Europe Neuroprotective Drugs Market Share by Type
    Table Europe Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table Europe Neuroprotective Drugs Sales Market Share by Application (2016-2025)
    Figure 2017 Europe Neuroprotective Drugs Market Share by Application
    Table Europe Neuroprotective Drugs Sales by Company (2016-2018) (K Units)
    Table Europe Neuroprotective Drugs Sales Market Share by Company (2016-2018)
    Figure Europe Neuroprotective Drugs Sales Market Share by Company in 2017
    Figure Asia Pacific Neuroprotective Drugs Sales Growth Rate 2016-2025 (K Units)
    Figure Asia Pacific Neuroprotective Drugs Revenue Growth Rate 2016-2025 (Million US$)
    Table Asia Pacific Neuroprotective Drugs Sales by Countries (2016-2025) (K Units)
    Table Asia Pacific Neuroprotective Drugs Sales Market Share by Countries (2016-2025)
    Figure 2017 Asia Pacific Neuroprotective Drugs Sales Market Share by Countries
    Table Asia Pacific Neuroprotective Drugs Revenue by Countries (2016-2025) (Million US$)
    Table Asia Pacific Neuroprotective Drugs Revenue Market Share by Countries (2016-2025)
    Figure 2017 Asia Pacific Neuroprotective Drugs Revenue Market Share by Countries
    Figure China Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure China Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Japan Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Japan Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Korea Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Korea Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure India Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure India Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Australia Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Australia Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Indonesia Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Indonesia Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Malaysia Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Malaysia Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Philippines Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Philippines Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Thailand Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Thailand Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Vietnam Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Vietnam Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Singapore Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Singapore Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Table Asia Pacific Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table Asia Pacific Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure 2017 Asia Pacific Neuroprotective Drugs Market Share by Type
    Table Asia Pacific Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table Asia Pacific Neuroprotective Drugs Sales Market Share by Application (2016-2025)
    Figure 2017 Asia Pacific Neuroprotective Drugs Market Share by Application
    Table Asia Pacific Neuroprotective Drugs Sales by Company (2016-2018) (K Units)
    Table Asia Pacific Neuroprotective Drugs Sales Market Share by Company (2016-2018)
    Figure Asia Pacific Neuroprotective Drugs Sales Market Share by Company in 2017
    Figure Central & South America Neuroprotective Drugs Sales Growth Rate 2016-2025 (K Units)
    Figure Central & South America Neuroprotective Drugs Revenue Growth Rate 2016-2025 (Million US$)
    Table Central & South America Neuroprotective Drugs Sales by Countries (2016-2025) (K Units)
    Table Central & South America Neuroprotective Drugs Sales Market Share by Countries (2016-2025)
    Figure 2017 Central & South America Neuroprotective Drugs Sales Market Share by Countries
    Table Central & South America Neuroprotective Drugs Revenue by Countries (2016-2025) (Million US$)
    Table Central & South America Neuroprotective Drugs Revenue Market Share by Countries (2016-2025)
    Figure 2017 Central & South America Neuroprotective Drugs Revenue Market Share by Countries
    Figure Brazil Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Brazil Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Argentina Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Argentina Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Table Central & South America Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table Central & South America Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure 2017 Central & South America Neuroprotective Drugs Market Share by Type
    Table Central & South America Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table Central & South America Neuroprotective Drugs Sales Market Share by Application (2016-2025)
    Figure 2017 Central & South America Neuroprotective Drugs Market Share by Application
    Table Central & South America Neuroprotective Drugs Sales by Company (2016-2018) (K Units)
    Table Central & South America Neuroprotective Drugs Sales Market Share by Company (2016-2018)
    Figure Central & South America Neuroprotective Drugs Sales Market Share by Company in 2017
    Figure Middle East and Africa Neuroprotective Drugs Sales Growth Rate 2016-2025 (K Units)
    Figure Middle East and Africa Neuroprotective Drugs Revenue Growth Rate 2016-2025 (Million US$)
    Table Middle East and Africa Neuroprotective Drugs Sales by Countries (2016-2025) (K Units)
    Table Middle East and Africa Neuroprotective Drugs Sales Market Share by Countries (2016-2025)
    Figure 2017 Middle East and Africa Neuroprotective Drugs Sales Market Share by Countries
    Table Middle East and Africa Neuroprotective Drugs Revenue by Countries (2016-2025) (Million US$)
    Table Middle East and Africa Neuroprotective Drugs Revenue Market Share by Countries (2016-2025)
    Figure 2017 Middle East and Africa Neuroprotective Drugs Revenue Market Share by Countries
    Figure GCC Countries Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure GCC Countries Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Turkey Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Turkey Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure Egypt Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure Egypt Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Figure South Africa Neuroprotective Drugs Sales Growth Rate (2016-2025) (K Units)
    Figure South Africa Neuroprotective Drugs Revenue Growth Rate (2016-2025) (Million US$)
    Table Middle East and Africa Neuroprotective Drugs Sales by Type (2016-2025) (K Units)
    Table Middle East and Africa Neuroprotective Drugs Sales Market Share by Type (2016-2025)
    Figure 2017 Middle East and Africa Neuroprotective Drugs Market Share by Type
    Table Middle East and Africa Neuroprotective Drugs Sales by Application (2016-2025) (K Units)
    Table Middle East and Africa Neuroprotective Drugs Sales Market Share by Application (2016-2025)
    Figure 2017 Middle East and Africa Neuroprotective Drugs Market Share by Application
    Table Middle East and Africa Neuroprotective Drugs Sales by Company (2016-2018) (K Units)
    Table Middle East and Africa Neuroprotective Drugs Sales Market Share by Company (2016-2018)
    Figure Middle East and Africa Neuroprotective Drugs Sales Market Share by Company in 2017
    Table Genervon Biopharmaceuticals (Canada) Company Details
    Table Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Genervon Biopharmaceuticals (Canada) Recent Development
    Table NeuroVive Pharmaceutical (Sweden) Company Details
    Table NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table NeuroVive Pharmaceutical (Sweden) Recent Development
    Table Ceregene (USA) Company Details
    Table Ceregene (USA) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Ceregene (USA) Recent Development
    Table BHRPharma (Thailand) Company Details
    Table BHRPharma (Thailand) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table BHRPharma (Thailand) Recent Development
    Table Neuren Pharmaceuticals (Australia) Company Details
    Table Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Neuren Pharmaceuticals (Australia) Recent Development
    Table Allon therapeutics (Canada) Company Details
    Table Allon therapeutics (Canada) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Allon therapeutics (Canada) Recent Development
    Table Bionure Inc. (USA) Company Details
    Table Bionure Inc. (USA) Neuroprotective Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
    Table Bionure Inc. (USA) Recent Development
    Figure GDP by Regions / Largest Economies Pie Chart in 2016
    Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
    Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
    Figure Saving Rate Total, % of GDP, 2015
    Table Neuroprotective Drugs Value Chain
    Table Typical Suppliers of Key Neuroprotective Drugs Raw Material
    Table Neuroprotective Drugs Customers List
    Table Neuroprotective Drugs Sales Channels
    Table Neuroprotective Drugs Distributors List
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources

Latest News

31-Oct-2018 | Medical Care

Obesity, low BMI linked to increased risk of death, study reveals

The study, published Wednesday in The Lancet Diabetes and Endocrinology and conducted by scientists at London School of Hygiene and Tropical Medicine, revealed that BMI that's either too high o ...

11-Aug-2018 | Electrical & Electronic Device

Samsung leads the pack, Smartphone Market in India Grows 29% In Third Quarter

The shipments of mobile in India are expected to reach the mark of 262 Million units till the fourth quarter arrives. Relying on the numbers, vendors dealing in mobile shipped approximately 80 Mill ...

18-Jul-2018 | Chemicals & Materials

It is Possible!! Can News Reports Be Automated?

Artificial intelligence is currently the hot topic of the town owing to its efficiency and quick work. It is a technology that is currently being used for a number of applications in the various se ...

26-Jun-2018 | Electrical & Electronic Device

Vodafone to Make Stronger Enterprise Portfolio Thus Bolstering Global Telecom Market

Vodafone India is seeking at the broadband segment to fortify its venture portfolio, said the Sunil Sood, the MD and CEO of the telecom company. The carriers had posted 2x development in the enterp ...

17-Apr-2018 | Food Service & Hospitality

Beneficiaries In Puducherry Don’t Use Subsidy To Purchase Food Grain

The Union Food Ministry has received a request from the administration of Puducherry for crediting the subsidy to the beneficiaries’ bank accounts rather than the system distributing subsidiz ...